Clinical trial NCT00545766: Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Official title: A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostate Cancer
Keywords: Prostate Cancer
Hormone Refractory
Vinflunine
Salvage Chemotherapy
Lead sponsor: SCRI Development Innovations, LLC
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
First posted: 2007-10-17
Enrollment: 41
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients with HRPC, many of whom retain an excellent performance status. The antitumor characteristics and toxicity profile of vinflunine make it an ideal agent to be investigated in this setting. In this Phase II trial, we plan to evaluate the efficacy, toxicity, and feasibility of administering IV vinflunine at a dose of 320 mg/m2 q3w as salvage chemotherapy in patients with HRPC. The patients will be evaluated for response, survival, and toxicity. If significant antitumor activity is demonstrated, further evaluation of this agent either alone or combination regimens and at earlier stages of disease will be indicated.

Detailed description: This is a non-randomized (single-arm), open-label, multi-center, single-agent, Phase II study of vinflunine as second- or third-line treatment of subjects with HRPC. The primary objective of the study is to evaluate the efficacy of vinflunine in the salvage treatment, as measured by Protein-Specific Antigen (PSA) Response Rate endpoint.

The primary objective of this study is as follows:

To evaluate the efficacy (as measured by the PSA response rate) of IV vinflunine administered q3w in HRPC patients who have progressed after one or two previous chemotherapy regimens.

Secondary Objectives

The secondary objectives of this study are as follows:

* To evaluate the efficacy of IV vinflunine administered q3w in HRPC patients who have previously received chemotherapy (one or two regimens), as measured by:

  * Time to PSA progression
  * Overall survival
  * Palliative response in patients with an Analgesic Score (AS) ≥10 and stable baseline pain
  * Health-Related Quality of Life
* To assess the efficacy (as measured by the PSA response rate) of IV vinflunine in HRPC patients based on their response to prior chemotherapy
* Chemotherapy responsive - previous response to most recent chemotherapy regimen lasting \>2 months after completion.
* Chemotherapy refractory - failure to respond to, or progression during or within three months of completing last chemotherapy.
* To assess the response rate to IV vinflunine in the subset of patients with measurable disease, as measured by traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Therasse et al. 2000).
* To evaluate the safety of IV vinflunine administered every three weeks in HRPC patients who have previously received chemotherapy.

Eligibility criteria: Inclusion Criteria:

Men age 18 years of age or older who have HRPC are eligible for this study based on the following inclusion criteria:

1. Histologically confirmed adenocarcinoma of the prostate.
2. Progressive hormone refractory locally advanced or metastatic disease.

   * (Definition of HRPC): Clinical or serological evidence of disease progression despite adequate anti-androgen therapy, documented by castrate levels of serum testosterone (\<50 ng/mL).
   * Patients on medical castration therapy should continue on treatment to maintain castrate levels of serum testosterone. Patients receiving anti-androgen or estrogen therapy should either be maintained on it, or have documented progression 4 weeks after withdrawal of all agents (except nilutamide and bicalutamide), which requires 6 weeks.
3. Disease Progression, documented by any of the following:

   * PSA Progression, documented by an elevated PSA level (\>5 ng/mL), which has risen serially from the baseline PSA value (PSA value #1) on two occasions, each at least 1 week apart (these will be considered PSA values #2 and #3). (Note: if the level of PSA value #3 is less than the level of PSA value #2, a subsequent PSA value must be obtained (PSA value #4) at least 1 week after PSA value #3 was measured. In order for this event to be considered a PSA progression, the level of this final PSA value (PSA value #4) must be greater than the PSA level that was observed for PSA value #2.
   * Progressive metastatic prostate carcinoma, documented by computed tomography (CT), magnetic resonance imaging (MRI), or radiograph of non osseous lesions (see Section 7.2).
   * Bone Scan Progression, documented by the appearance of at least one or more new lesions that are not believed to be secondary to tumor flare phenomenon.
4. Patients with bone only disease must have a PSA level \>=5 ng/mL; patients with stable lesions must have evidence of PSA progression. Patients must have radiographically or clinically demonstrable metastatic disease.
5. Receipt of either 1 or 2 previous chemotherapy regimens; one of these regimens must have included docetaxel.
6. ECOG performance status of 0-2.
7. Adequate bone marrow function, defined by: white blood cells \>=3,500/uL, hemoglobin \>=8 g/dL, platelet count \>=100,000/uL.
8. Adequate renal function, defined by: serum creatinine \<1.8 mg/dL, or calculated or measured creatinine clearance (GFR) of \>=60 cc/min. Patients with a creatinine clearance of \>30 mL/min but \<60 mL/min may also be enrolled, but will require an initial adjusted dose (see Section 5.1)
9. Adequate hepatic function, defined by: total bilirubin \<1.5 x the upper limit of normal, AST \<2 x the upper limit of normal.
10. Patients must be able to comprehend the nature of the study and provide written informed consent.
11. Partners of women of childbearing potential must use effective contraception while on treatment and for at least 3 months thereafter. Women of childbearing potential include females who have experienced menarche and have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not post-menopausal (i.e., amenorrhea \>12 months).
12. Patients on bisphosphonate therapy (at the discretion of the investigator).

Exclusion Criteria:

1. History of other prior malignancy in the past 5 years (excluding resected basal cell or squamous cell skin cancer).
2. History of second- or third-degree heart block, uncontrolled angina, uncontrolled hypertension, or recent myocardial infarction or congestive heart failure (New York Heart Association Class III-IV) within the past 6 months (see Appendix F)
3. Cerebral vascular accident within the past 6 months.
4. Peripheral neuropathy \> grade 2 per Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
5. Patients with rising PSA but no demonstrable metastases.
6. Previous radiotherapy, outside of standard portals, utilized for prostate cancer (if total amount of radiotherapy encompasses \>25% of bone marrow containing osseous regions).
7. Prior therapy with Strontium 90, Samarium 150, or other injectable therapeutic radioisotopes.
8. History of prior allergic reaction to any vinca alkaloid.
9. Use of chemotherapy or investigational drugs within 4 weeks prior to the first dose of study drug.
10. Treatment with ketoconazole, itraconazole, ritonavir, amprenavir, or indinavir within 4 weeks prior to the first dose of study drug.
11. Previous treatment with an anthracycline.
12. Patients who are unable to receive chemotherapy on a basis of once every three weeks as a result of physical, environmental, or co existent medical problems.

Primary outcomes:
measure: Protein-specific Antigen (PSA) Response Rate
timeFrame: 18 months
Secondary outcomes:
measure: Time to PSA Progression
timeFrame: 18 months
measure: Progression Free Survival
timeFrame: 18 months
measure: Number of Participants Experiencing Overall Survival (OS)
timeFrame: 18 months
Other outcomes:
Locations:
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Jacksonville
country: United States
facility: Integrated Community Oncology Network
state: Florida
city: Orlando
country: United States
facility: Florida Hospital Cancer Institute
state: Florida
city: Gainesville
country: United States
facility: Northeast Georgia Medical Center
state: Georgia
city: Louisville
country: United States
facility: Consultants in Blood Disorders and Cancer
state: Kentucky
city: Cincinnati
country: United States
facility: Oncology Hematology Care
state: Ohio
city: Drexel Hill
country: United States
facility: Consultants in Medical Oncology and Hematology
state: Pennsylvania
city: Chattanooga
country: United States
facility: Associates in Hematology Oncology
state: Tennessee
city: Chattanooga
country: United States
facility: Chattanooga Oncology Hematology Associates
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: San Antonio
country: United States
facility: South Texas Oncology and Hematology
state: Texas
city: Newport News
country: United States
facility: Peninsula Cancer Institute
state: Virginia
Study officials:
affiliation: SCRI Development Innovations, LLC
name: John D. Hainsworth, M.D.
role: STUDY_CHAIR
References:
citation: Hainsworth JD, Meluch AA, Lane CM, Spigel DR, Burris HA 3rd, Gandhi JG, Crane EJ, Stipanov MA, Greco FA. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium. Cancer Invest. 2010 Mar;28(3):275-9. doi: 10.3109/07357900902918460.